

Breakthrough Chemistry Inc. Issues Comprehensive Shareholder Update

2025: A Transformational Year for Breakthrough Chemistry Inc.

BONITA SPRINGS, FL, January 5, 2026 / (OTCID: BKTH– Breakthrough Chemistry, Inc., a Nevada-based corporation headquartered in Bonita Springs, FL, with a groundbreaking portfolio of cutting-edge, eco-friendly products designed to revolutionize industries and establish leadership in pioneering chemical solutions, today announced a comprehensive shareholder update summarizing the Company's restructuring achievements in 2025, recent material events, and strategic focus for 2026.

Dear Shareholders,

Breakthrough Chemistry, Inc. has reached a defining moment in its transformation. Throughout 2025, our team remained focused on rebuilding the Company from the inside out, strengthening our balance sheet, resolving legacy obligations, validating our technology platforms, and positioning BKTH for long-term, scalable growth. The work completed this past year has reshaped the Company's structure, clarified its strategic direction, and established the strongest foundation in our history.

2025 was a year of disciplined execution. We eliminated legacy debt, retired more than 600 million shares of potential dilution, completed a major IP transaction, and advanced commercialization initiatives across each of our core chemistry platforms. These actions have given BKTH a clean, modernized structure and a technology portfolio capable of supporting expansion across North America and the Indo-Pacific region.

As we enter 2026, our focus turns to unlocking the full value of our chemistry platforms through licensing, strategic partnerships, and targeted international growth. With a diverse suite of disruptive technologies serving multiple vertical markets and with new opportunities emerging across global supply chains, BKTH is positioned for meaningful acceleration in the year ahead.

Strengthening Our Corporate Identity

Early in 2025, the Company completed its transition from Megola Inc. to Breakthrough Chemistry Inc. (BKTH), including the corporate name change, new trading symbol, and updated public-company disclosures. This transition aligned our public identity with our chemistry-driven IP portfolio and long-term commercialization strategy.

Governance and Leadership Alignment

In February, BKTH implemented leadership changes and board resignations as part of its broader restructuring plan. These adjustments streamlined governance and aligned management with our IP-centric, asset-light operating model.

Medesol Agreement Fully Restructured

One of the most significant balance-sheet improvements of 2025 was the comprehensive amendment of the Company's legacy agreements with Medesol Global. The revised structure removed substantial dilution, eliminated multiple debt obligations, secured key intellectual property, and established a simplified commercial framework going forward. Key terms included:

- Return of 49,000 Series D Preferred Shares (equivalent to 490,000,000 common shares on a fully diluted basis)
- Elimination of all Medesol-related debt, including:
 - Forgiveness of a \$40,330 payable
 - Cancellation of a \$25,000 convertible note plus accrued interest
- Assignment of all SiO₂-related intellectual property to BKTH, superseding prior agreements
- Streamlined commercial terms, including clarified rights related to Medesol's legacy formulation portfolio
- Inventory adjustments, including Medesol taking possession of expired inventory and issuing BKTH a \$35,832.75 royalty credit

This restructuring removed a major legacy overhang, reduced nearly half a billion shares of potential dilution, eliminated over \$65,000 in liabilities, secured key IP assets, and simplified the Company's commercial framework.

Capital Structure Modernization

BKTH successfully completed all FINRA corporate actions, including the name and symbol change, 1:30 reverse split, and authorized share reduction from 3.05B to 1.55B. The Company also advanced to the OTCIQ tier, reflecting improved reporting discipline and transparency. These actions modernized our capital structure and improved readiness for future growth initiatives.

In addition, BKTH further retired another 12,500 Series D Preferred Shares (equivalent to 125,000,000 common shares on a fully diluted basis), further reducing potential dilution and reinforcing our long-term capitalization strategy.

Hartindo Product Line Expansion

In 2025, BKTH expanded its retained fire-inhibitor platform by adding the remaining Hartindo product lines to its portfolio. These formulations were transferred by GS Capital Blends LLC at no additional stock compensation, strengthening the Company's fire-chemistry suite prior to the GEVI transaction. BKTH also harmonized the Hartindo blends with its existing documentation and formulation standards, ensuring regulatory consistency and supporting future licensing and commercialization opportunities across industrial, consumer, and specialty markets.

GEVI IP Transaction Completed

On December 26, 2025, BKTH finalized the sale of a defined group of intellectual property assets to General Enterprise Ventures Inc. (NYSE American: CTR) in a transaction valued at \$1,882,000, consisting of \$100,000 in cash and 220,000 shares of CTR common stock. The

assets transferred included BKTH's wildfire and structural fire-prevention technologies. BKTH retains all other fire-inhibitor chemistries, stabilized halogen oxidizers, and SiO₂ coating platforms.

CellHelmet MOU Update

In late 2025, BKTH entered a non-binding MOU to explore the potential acquisition of Kane & McHenry Enterprises LLC, dba CellHelmet. BKTH continues to engage in constructive discussions with owners of K&M, with both companies actively exploring strategic options to align operations and create shareholder value. These discussions remain ongoing, and a decision on the path forward is expected within BKTH's Q4, ending March 31, 2026.

Winner Medical / SAP Program Update

BKTH initiated a pilot program with Winner Medical earlier in 2025; however, internal restructuring at Winner, combined with broader global tariff pressures, slowed their ability to advance the project on the original timeline. Rather than wait for external conditions to resolve, BKTH has shifted its strategy and is now working with its Asia-Pacific licensing partner, currently in active negotiations to assume all commercial dialogue with Winner and to engage additional SAP and zeolite-coating manufacturers across the region. In parallel, BKTH has also been in discussions with several U.S.-based manufacturers to ensure multiple commercialization pathways remain active and to broaden the Company's footprint across both domestic and international markets.

2026 Strategic Focus

Looking ahead to 2026, BKTH will focus on expanding its zeolite coatings platform through licensing agreements with major processors; advancing its retained fire-inhibitor chemistries into industrial, consumer, and specialty applications; and accelerating global distribution of its SiO₂ liquid-glass technologies through both CellHelmet and new international channels. The Company is also pursuing non-dilutive funding opportunities. Together, these initiatives position BKTH for scalable, IP-driven growth across multiple high-value vertical markets.

Sincerely,

Robert Gardiner

Chief Executive Officer

Breakthrough Chemistry, Inc.

About Breakthrough Chemistry Inc. (BKTH)

Breakthrough Chemistry Inc. (OTCID: BKTH) develops and commercializes environmentally responsible chemical solutions across three core platforms: stabilized halogen oxidizers, eco fire inhibitors, and silicon dioxide coatings. The company is committed to challenging legacy chemical paradigms and delivering scalable, certifier-friendly innovations. BKTH is headquartered in Bonita Springs, FL.

Breakthrough Chemistry Inc

Mark Suchy

<https://breakthroughchemistry.com>

<http://twitter.com/megolacorp>

IR@breakthroughchemistry.com

1 800-549-6970

Stock information here: <https://www.otcmarkets.com/stock/BKTH/overview>

BKTH is in process of changing social sites to reflect new name and symbol

Forward-Looking Statements The statements contained in this release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "could," "should," "expect," "plan," "project," "intend," "anticipate," "believe," "estimate," "predict," "potential," "pursuant," "target," "continue," and similar expressions are intended to identify such forward looking statements. The statements in this press release that are not historical statements, including statements regarding BKTH's plans, objectives, future opportunities for BKTH's services, future financial performance and operating results and any other statements regarding BKTH's future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward looking statements within the meaning of the federal securities laws. These statements are not guarantees